FDA accepts IND application for UGN-103 in NMIBC
The IND will initiate the launch of a phase 3 study to explore the safety and efficacy of UGN-103 in patients with low-grade, intermediate-risk NMIBC.
The IND will initiate the launch of a phase 3 study to explore the safety and efficacy of UGN-103 in patients with low-grade, intermediate-risk NMIBC.
A phase 3 trial demonstrates a high rate of complete response with cretostimogene, an investigational immunotherapy administered intravesically.
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
AUA 2024 advanced prostate cancer, molecular imaging (mi) node positive disease (miN1) undergoing radical prostatectomy, extended pelvic lymph node dissection (ePLND).
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
Extended lymph node dissection during radical cystectomy offered no additional overall survival or disease-free survival benefit vs standard lymph node dissection.
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
The 2024 AUA Annual Meeting program will offer more education and innovative programming than ever before! Join us in San Antonio.
renal mass, renal cell carcinoma (RCC), kidney cancer, Partial Nephrectomy (PN), Radical Nephrectomy (RN), renal mass in a solitary kidney (RMSK), chronic kidney disease (CKD),…
The AUA invites the global urologic community to the 119th AUA Annual Meeting in the dynamic city of San Antonio, TX!